Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (7461)	12/2/1997 1:07:00 PM
From: EagleC	Read Replies (1) \| Respond to of 14328

Keiko, do you hear of any industry buzz in Europe regarding UNI-Gold products? Since these are currently available it seems useful to know the reception these products receive. It seems the scientific/medical community there gives us the reality check we may all need on product usefulness,innovative technology, etc. Our obsession with US FDA approval, while certainly not hurting future performance and acceptance, doesn't necessarily mean we're automatically swimming in future profit streams. What do you think? I keep buying more...keeps life interesting.

To: Keiko who wrote (7461)	12/4/1997 3:11:00 PM
From: Ace	Read Replies (4) \| Respond to of 14328

Irish companies perform well in financial review of European biotech industry A review of the financial results of both publicly quoted and private European biotechnology companies contained encouraging news for Ireland. Performed and published by Nature Biotechnology this autumn, the review shows 2 Irish companies, (Elan and Trinity Biotech) in the top 20 publicly listed companies examined. The 20 companies are dominated by those from the UK, (12) with an additional 2 from Denmark, and one each from France, Germany, Belgium and Switzerland while Elan and Trinity Biotech are at numbers 3 and 19 respectively. The top company was Novo-Nordisk, (Denmark) with 1996 revenues of 1915.6 million ECUs. An additional survey of private European biotechnology companies showed the Irish company Biotrin Holdings at number 11. The top company in this sector was BioMerieux, (France) with a 1996 revenue of 417 million ECUs. The review showed that the results of the examined companies were up 12.65 compared to 1995 and that 3 companies account for more than 80% of European biotechnology company revenue. They are Novo-Nordisk, Ares-Serono, (Switzerland) and BioMerieux. Full details in: "European biotechnology companies grow by 12.6%" Lahtteenmaki, R., pp: 6-9, Nature Biotechnology, EuroProduct Focus, Autumn 1997.